# Visceral fat around menopause: why the scale can miss a change

Research finds changes in abdominal fat and lean mass during menopause. What those findings mean, and what a waist measurement cannot prove.

Canonical: https://velri.co/blog/perimenopause-visceral-fat-shift-strength-seeker
Publisher: Velri (https://velri.co/about)
Published: 2026-07-17
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Body composition can change during the menopause transition without an equally striking change on the scale. Research has found increases in fat mass and declines in lean mass around this period, changes that can partly offset one another in total body weight. [1]

## What studies have observed

In the longitudinal SWAN study, the rate of fat gain accelerated and lean mass began to decline during the transition. Total weight did not show the same acceleration. The study followed changes over time rather than testing a treatment. [1]

A separate SWAN Heart analysis followed 362 women and examined visceral adipose tissue, the fat within the abdomen. Visceral fat accumulation accelerated in the years around the final menstrual period. During part of the transition, greater visceral fat was associated with a measure of thickening in the internal carotid artery wall. [2]

That was an association in an observational study. It does not predict one person’s cardiovascular outcome or prove that menopause alone caused the change. [2]

## What visible changes can and cannot tell you

A change in clothing fit can make this shift noticeable. It cannot quantify visceral fat or establish the reason for a metabolic change. The research used body-composition measurements, not appearance alone. [1][2]

Metabolic assessment answers a separate question. NIDDK identifies abdominal body fat as one risk factor for insulin resistance, but prediabetes is assessed with glucose-based tests such as A1c, fasting glucose or an oral glucose tolerance test. Insulin resistance itself often has no symptoms. [3]

The useful interpretation combines what has changed in body composition with actual health measurements.

## Sources
[1] Changes in body composition and weight during the menopause transition. (2019). https://pubmed.ncbi.nlm.nih.gov/30843880/
[2] Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis: the SWAN heart study. (2021). https://pubmed.ncbi.nlm.nih.gov/33651741/
[3] Insulin Resistance & Prediabetes - NIDDK (2025). https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support